Compare TXG & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TXG | MLYS |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.2B |
| IPO Year | 2019 | 2023 |
| Metric | TXG | MLYS |
|---|---|---|
| Price | $24.95 | $27.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 6 |
| Target Price | $17.61 | ★ $48.67 |
| AVG Volume (30 Days) | ★ 2.2M | 1.2M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 76.97 | 37.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $245,893,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 68.06 | N/A |
| 52 Week Low | $7.26 | $12.59 |
| 52 Week High | $24.30 | $47.65 |
| Indicator | TXG | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 70.86 | 53.22 |
| Support Level | $11.62 | $26.85 |
| Resistance Level | N/A | $31.09 |
| Average True Range (ATR) | 1.14 | 1.65 |
| MACD | 0.41 | 0.38 |
| Stochastic Oscillator | 93.57 | 62.11 |
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.